# Evaluation of KX2-391 in Patients With Advanced Malignancies

> **NCT00658970** · PHASE1 · COMPLETED · sponsor: **Athenex, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Solid Tumors
- Lymphoma

## Interventions

- **DRUG:** KX2-391

## Key facts

- **NCT ID:** NCT00658970
- **Lead sponsor:** Athenex, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2010-03
- **Final completion:** 2011-05
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00658970

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00658970, "Evaluation of KX2-391 in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00658970. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*